Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.37 |
| ▸ | DGKA | P23743 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151117 | 0.93 | USP2 (0.62) | USP2PLA2G2CKDM4EDUSP3MEN1 | |
| SCHEMBL6150701 | 0.93 | USP2 (0.62) | USP2PLA2G2CKDM4EDUSP3MEN1 | |
| SCHEMBL8488063 | 0.88 | USP2 (0.50) | USP2PLA2G2CKDM4EDUSP3MEN1 | |
| SCHEMBL6150204 | 0.84 | DGKA (0.55) | USP2PLA2G2CKDM4EDUSP3MEN1 | |
| SCHEMBL6150627 | 0.84 | DGKA (0.55) | USP2PLA2G2CKDM4EDUSP3MEN1 | |
| SCHEMBL6150941 | 0.84 | DGKA (0.55) | USP2PLA2G2CKDM4EDUSP3MEN1 | |
| SCHEMBL12214864 | 0.83 | TSHR (0.49) | USP2PLA2G2CKDM4EDUSP3MEN1 | |
| SCHEMBL946974 | 0.82 | USP2 (0.53) | USP2PLA2G2CKDM4EDUSP3MEN1 | |
| Acetic Acid SCHEMBL27692051 | 0.79 | USP2 (0.70) | USP2PLA2G2CKDM4EDUSP3MEN1 | |
| SCHEMBL28555138 | 0.79 | KDM4E (0.62) | USP2KDM4EDUSP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868955-B2 | Human toll-like receptor inhibitors and methods of use thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2900823-B1 | HUMAN TOLL-LIKE RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | DYNAVAX TECH CORP (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2209896-B1 | METHODS AND COMPOSITIONS FOR INHIBITION OF IMMUNE RESPONSES AND AUTOIMMUNITY | DYNAVAX TECH CORP (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2361980-B1 | Methods and compositions for inhibition of immune responses and autoimmunity | DYNAVAX TECH CORP (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9476053-B2 | Methods and compositions for inhibition of immune responses and autoimmunity | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2016-10-25 | — | — | US | disclosed |
| US-9347064-B2 | Methods of treatment using TLR7 and/or TLR9 inhibitors | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2582398-B1 | METHODS OF TREATMENT USING TLR7 AND/OR TLR9 INHIBITORS | DYNAVAX TECH CORP (US) | 2016-04-13 | — | — | EP | disclosed |
| US-9228184-B2 | Human toll-like receptor inhibitors and methods of use thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150297737-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV | DYNAVAX TECHNOLOGIES CORPORATION | 2015-10-22 | — | — | US | disclosed |
| US-20150275216-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF IMMUNE RESPONSES AND AUTOIMMUNITY | DYNAVAX TECHNOLOGIES CORPORATION | 2015-10-01 | — | — | US | disclosed |
| WO-2006028742-A2 | METHODS AND CONPOSITIONS FOR INHIBITION OF INNATE IMMUNE RESPONSES AND AUTOIMMUNITY | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1625140-A2 | BRANCHED IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME | Dynavax Technologies Corporation (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20040136948-A1 | Branched immunomodulatory compounds and methods of using the same | DYNAVAX TECHNOLOGIES CORPORATION | 2004-07-15 | — | — | US | disclosed |
| WO-2004058159-A2 | BRANCHED IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040132677-A1 | Chimeric immunomodulatory compounds and methods of using the same-IV | DYNAVAX TECHNOLOGIES CORPORATION | 2004-07-08 | — | — | US | disclosed |
| EP-1404873-A2 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME | Dynavax Technologies Corporation (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030225016-A1 | Chimeric immunomodulatory compounds and methods of using the same - III | DYNAVAX TECHNOLOGIES CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-20030199466-A1 | For modulating an immune response | DYNAVAX TECHNOLOGIES CORPORATION | 2003-10-23 | — | — | US | disclosed |
| US-20030175731-A1 | Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies | DYNAVAX TECHNOLOGIES CORPORATION | 2003-09-18 | — | — | US | disclosed |
| WO-2003000922-A2 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199466-A1 | For modulating an immune response | IFNG, ICOS, CD47 | USP2 1629/4885PLA2G2C 2254/4885KDM4E 1282/4885 |
| US-20030175731-A1 | Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies | TSLP, CD74, MICA | USP2 2702/4885PLA2G2C 741/4885KDM4E 4540/4885 |
| US-20040132677-A1 | Chimeric immunomodulatory compounds and methods of using the same-IV | ICOS, CD47, IL2 | USP2 3046/4885PLA2G2C 738/4885KDM4E 594/4885 |
| US-20150297737-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV | ICOS, CD47, IL2 | USP2 3046/4885PLA2G2C 738/4885KDM4E 594/4885 |
| US-20030225016-A1 | Chimeric immunomodulatory compounds and methods of using the same - III | CD47, ICOS, IL2 | USP2 2510/4885PLA2G2C 1087/4885KDM4E 1556/4885 |
| US-20040136948-A1 | Branched immunomodulatory compounds and methods of using the same | IFNG, ICOS, IL2 | USP2 2873/4885PLA2G2C 2226/4885KDM4E 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.